|
|
Volumn 101, Issue 7, 2009, Pages 448-449
|
|
Trastuzumab before breast surgery? Large trial says yes but does not quell debate
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIRUBICIN;
LAPATINIB;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
QUINAZOLINE DERIVATIVE;
TUMOR MARKER;
ADJUVANT THERAPY;
ADVANCED CANCER;
BREAST CANCER;
BREAST SURGERY;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER SURVIVAL;
CARDIOTOXICITY;
DRUG MEGADOSE;
HEART DISEASE;
HUMAN;
INTRADUCTAL CARCINOMA;
MASTECTOMY;
NOTE;
PARTIAL MASTECTOMY;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
CHEMISTRY;
CLINICAL TRIAL;
DRUG EFFECT;
FEMALE;
HEART;
HEART FAILURE;
METHODOLOGY;
ANTHRACYCLINES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
FEMALE;
HEART;
HEART FAILURE;
HUMANS;
NEOADJUVANT THERAPY;
QUINAZOLINES;
RECEPTOR, ERBB-2;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 63649133018
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp072 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|